Effectiveness of Beclomethasone Dipropionate Nasal Aerosol for Perennial Allergic Rhinitis

Inclusion Criteria:

- Male or female

- Age 12 years or greater at time of enrollment

- Diagnosis of PAR for at least one year; and 2)a positive skin prick (ie,
epicutaneous) or serum-specific IgE test within the past 2 years to a perennial
allergen as appropriate for the location; and 3)PAR symptoms that are consistent with
exposure to this allergen for at least one year

- Uncontrolled rhinitis symptoms at the time of assessment as confirmed by a score of
21 or less on the RCAT

- Newly prescribed BDP Nasal Aerosol (within the past 7 days but have not yet used)

- Willing and able to complete surveys in English on a computer with internet access

- Willing and able to provide informed consent prior to entering the study (or
parent/caregiver/legal guardian if applicable)

Exclusion Criteria:

- Current acute or chronic sinusitis or chronic purulent nasal discharge

- Rhinitis medicamentosa or nasal structural abnormalities (including nasal polyps and
clinically significant septal deviation) that significantly interfere with nasal
airflow

- Acute upper respiratory infection within the past 14 days

- Used any pressurized metered-dose inhaler INS product (including BDP Nasal Aerosol
and Ciclesonide Nasal Aerosol) within the past 90 days

- Used any experimental therapy for AR within the past 30 days

- Any condition which the investigator feels may interfere with the study